Premium
Efficacy of uric acid‐lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients
Author(s) -
Wu Jing,
Zhang YuPing,
Qu Yuan,
Jie LiGang,
Deng JiaXin,
Yu QingHong
Publication year - 2019
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13652
Subject(s) - benzbromarone , febuxostat , medicine , hypertriglyceridemia , allopurinol , gout , uric acid , fenofibrate , triglyceride , gastroenterology , hyperlipidemia , cholesterol , hyperuricemia , endocrinology , xanthine oxidase inhibitor , xanthine oxidase , diabetes mellitus , biochemistry , chemistry , enzyme
Aim To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid‐lowering therapy (UALT). Methods A retrospective study was performed from January 2015 to December 2017 in gouty patients receiving UALT. A total of 124 gouty patients with hypercholesterolemia or hypertriglyceridemia who were administered UALT were monitored. Of the 124 patients with gout, 52 were treated with febuxostat, 29 were treated with allopurinol, and 43 were treated with benzbromarone. Cholesterol and triglyceride levels were recorded and analyzed following treatment for 8‐10 weeks. Results We compared the efficacy of febuxostat, allopurinol, and benzbromarone. All therapies mildly influenced serum cholesterol and triglyceride levels. Febuxostat significantly decreased cholesterol and triglyceride levels in patients who did not receive lipid‐lowering therapy. Allopurinol and benzbromarone modestly decreased triglyceride levels, but cholesterol levels were unaffected. Conclusion Uric acid‐lowering therapy benefits hyperlipidemia in gouty patients. Febuxostat effectively improved serum cholesterol and triglyceride levels compared to allopurinol and benzbromarone in patients with gout.